ClinicalTrials.gg
CompletedNCT05709626PREMIUMUpdated Nov 9, 2026

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

A Phase 4 interventional study of No aspirin (Prasugurel monotherapy) and 12-month DAPT in ST-segment Elevation Myocardial Infarction (STEMI), sponsored by Kindai University. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Kindai University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,268
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in ST Elevation Myocardial Infarction with a site in Japan — 1 open to participants now, 2 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Japan.

Started
2023
the only one that year
Phase 4
2 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Kindai University

Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, this one is the only one that started in 2023, is one of 2 in phase 4, and was the 9th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

1 of the 10 studies in ST Elevation Myocardial Infarction with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in ST Elevation Myocardial Infarction with a site in Japan, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Read the detailed description

In the STOPDAPT-2 ACS trial (NCT03462498), ischemic events (especially myocardial infarction) was significantly increased with 1-month DAPT followed by clopidogrel monotherapy, as compared to 12-month DAPT in patients with acute coronary syndrome (ACS). This was potentially attributable to clopidogrel, instead of prasugrel, which is more potent and has less individual difference in efficacy. On the other hand, previous studies including the STOPDAPT-2 ACS that evaluated the safety and efficacy of monotherapy with a P2Y12 inhibitor without aspirin consistently and significantly reduced the risk of bleeding, compared with standard DAPT. Consequently, there has been growing necessity to establish the safety with P2Y12 inhibitor monotherapy in terms of major adverse cardiovascular events. Therefore, we have planned to evaluate the non-inferiority of P2Y12 inhibitor monotherapy with prasugrel versus standard 12-month DAPT with prasugrel and aspirin in terms of the incidence of major cardiovascular events at 12 months after primary PCI in patients with STEMI using Platinum-Chromium Everolimus Eluting Stent (PtCr-EES; SYNERGYTM).

03

Conditions studied

  • ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

  • Acute Coronary Syndrome
  • Dual AntiPlatelet Therapy
  • Drug Eluting Stent
  • Percutaneous Coronary Intervention
  • ST-elevation myocardial infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
  • STEMI patients
  • Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months

Exclusion criteria

Exclusion Criteria:

  • Patients taking anticoagulants
  • Patients under 18 years old
  • Patients with less than 1 year prognosis
  • Patients participating in other intervention studies
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,268 participants (actual)

Study arms

  • Active comparator
    No aspirin (Prasugrel monotherapy)

    To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).

    Drug: No aspirin (Prasugurel monotherapy)

  • Active comparator
    12-month DAPT

    To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).

    Drug: 12-month DAPT

Interventions

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events

    Composite of all-cause death, myocardial infarction, or stroke

    Time frame: 12 months

Secondary outcomes

  1. Major secondary bleeding endpoint: Type 3 or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 3 or 5 bleeding defined by BARC criteria

    Time frame: 12 months

  2. All-cause death

    Death from any cause

    Time frame: 12 months

  3. Cardiovascular death

    Death from cardiovascular cause

    Time frame: 12 months

  4. Non-cardiovascular death

    Death from non-cardiovascular cause

    Time frame: 12 months

  5. Myocardial infarction (Periprocedual/ Spontaneous)

    Defined by the Academic Research Consortium (ARC)-2

    Time frame: 12 months

  6. Stroke (Ischemic/ Haemorrhagic)

    Including both ischemic and haemorrhagic stroke

    Time frame: 12 months

  7. Ischemic stroke

    Ischemic stroke with symptom lasting over 24 hours

    Time frame: 12 months

  8. Hemorrhagic stroke

    Intracerebral hemorrhage or subarachnoidal hemorrhage not associated with trauma

    Time frame: 12 months

  9. Stent thrombosis

    Stent thrombosis defined by Academic Research Consortium (ARC)-2 definition

    Time frame: 12 months

  10. Target lesion failure

    Cardiovascular death, target vessel myocardial infarction, clinically indicated target lesion revascularization

    Time frame: 12 months

  11. Target vessel failure

    Cardiovascular death, target vessel myocardial infarction, clinically indicated target vessel revascularization

    Time frame: 12 months

  12. Patient-Oriented Composite Endpoint

    All-cause death, stroke, myocardial infarction, and all revascularization, defined by the Academic Research Consortium (ARC)-2

    Time frame: 12 months

  13. Any target lesion revascularization

    Revascularization to the target lesions (including 5mm of both ends of the stent\[s\]) regardless of PCI or CABG

    Time frame: 12 months

  14. Clinically-driven target lesion revascularization

    Target lesion revascularization with the anginal symptoms or the positive test for ischemia

    Time frame: 12 months

  15. Non-target lesion revascularization

    Revascularization to non-target lesions regardless PCI or CABG

    Time frame: 12 months

  16. Coronary artery bypass grafting

    Any coronary artery bypass grafting

    Time frame: 12 months

  17. Any target vessel revascularization

    Revascularization to the target vessel

    Time frame: 12 months

  18. Any coronary revascularization

    Revascularization regardless of PCI or CABG

    Time frame: 12 months

  19. Type 2 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 2 bleeding defined by BARC criteria

    Time frame: 12 months

  20. Type 3 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 3 bleeding defined by BARC criteria

    Time frame: 12 months

  21. Type 4 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 4 bleeding defined by BARC criteria

    Time frame: 12 months

  22. Type 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 5 bleeding defined by BARC criteria

    Time frame: 12 months

  23. Type 2, 3, or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria

    Type 2, 3, or 5 bleeding defined by BARC criteria

    Time frame: 12 months

  24. Major bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria

    Major bleeding defined by TIMI criteria

    Time frame: 12 months

  25. Minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria

    Minor bleeding defined by TIMI criteria

    Time frame: 12 months

  26. Major or minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria

    Major or minor defined by TIMI criteria

    Time frame: 12 months

  27. Severe bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria

    Severe bleeding defined by GUSTO criteria

    Time frame: 12 months

  28. Moderate bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria

    Moderate bleeding defined by GUSTO criteria

    Time frame: 12 months

  29. Moderate or severe bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria

    Moderate or severe bleeding defined by GUSTO criteria

    Time frame: 12 months

  30. Intracranial bleeding

    Intracranial bleeding regardless of spontaneous or trauma

    Time frame: 12 months

  31. Gastrointestinal bleeding

    Bleeding from gastrointestinal tract regardless of severity

    Time frame: 12 months

  32. Gastrointestinal complaints

    Requirement of upper gastric fiberscopy to examine the gastrointestinal complaints

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Inaba S, Ogita M, Suwa S, Kashiwabara K, Wada H, Endo H, Shitara J, Nanasato M, Muramatsu T, Anzai H, Shirakabe A, Yamamoto M, Asaumi Y, Sakuma M, Okayama H, Takahashi K, Otake H, Ikari Y, Kozuma K, Morino Y, Nakazawa G. High Bleeding Risk and Aspirin Omission at the Time of Primary PCI in STEMI: A Post Hoc Analysis of the PREMIUM Trial. J Am Coll Cardiol. 2026 Oct 31:S0735-1097(26)10254-X. doi: 10.1016/j.jacc.2026.10.058. Online ahead of print. PubMed 42998063 ↗
  • Takahashi K, Kozuma K, Morino Y, Kashiwabara K, Otake H, Suwa S, Nanasato M, Muramatsu T, Anzai H, Shirakabe A, Yamamoto M, Asaumi Y, Sakuma M, Okayama H, Nakabayashi K, Ogata N, Jujo K, Wakabayashi K, Kusuyama T, Onishi Y, Ashida K, Mitsuhashi Y, Nishimoto Y, Yamazaki S, Kuriyama N, Ikari Y, Nakazawa G; PREMIUM Trial Investigators. Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI. N Engl J Med. 2026 Aug 29. doi: 10.1056/NEJMoa2606997. Online ahead of print. PubMed 42670955 ↗
  • Takahashi K, Kozuma K, Morino Y, Kashiwabara K, Otake H, Suwa S, Nanasato M, Muramatsu T, Anzai H, Shirakabe A, Yamamoto M, Asaumi Y, Sakuma M, Okayama H, Ikari Y, Nakazawa G. Prasugrel monotherapy versus 12-month dual antiplatelet therapy in STEMI patients undergoing intravascular imaging-guided PCI: Study design and rationale of the randomized PREMIUM trial. Cardiovasc Revasc Med. 2026 Aug;89:30-36. doi: 10.1016/j.carrev.2025.12.007. Epub 2025 Dec 11. PubMed 41436299 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Feb 2026, 34 months.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's 34 months is close to that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Feb 2023 → Apr 2023, primary completion Jan 2025 → Feb 2026 and completion Jan 2028 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2023
First posted
Feb 2, 2023
StartActual
Apr 7, 2023was Feb 2023
Primary completionActual
Feb 12, 2026was Jan 2025
CompletionActual
Apr 27, 2026was Jan 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Sites
1 site added, 1 site removed
Show site
  • Kindai University Faculty of Medicine · Sayama, Japan
Show 1 removed
  • Kindai University Faculty of Medicine · Osakasayama, Japan
Nov 9, 2026
Start date
Feb 28, 2023→Apr 7, 2023 (actual)
Nov 9, 2026
Primary completion
Jan 4, 2025→Feb 12, 2026 (actual)
Nov 9, 2026
Study completion
Jan 4, 2028→Apr 27, 2026 (actual)
Nov 9, 2026
Enrollment
2258 (estimated)→2268 (actual)
Nov 9, 2026
Publications
3 publications citing this study linked from PubMed, e.g. PubMed 42998063 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Publications 3 publications citing this study linked from PubMed, e.g. PubMed 42998063 ↗
    1 site added, 1 site removed
    Show site
    • Kindai University Faculty of Medicine · Sayama, Japan
    Show 1 removed
    • Kindai University Faculty of Medicine · Osakasayama, Japan
    Start date Feb 28, 2023→Apr 7, 2023 (now actual)
    Primary completion Jan 4, 2025→Feb 12, 2026 (now actual)
    Study completion Jan 4, 2028→Apr 27, 2026 (now actual)
    Enrollment 2258 (estimated)→2268 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05709626
Lead sponsor
Kindai University
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Apr 7, 2023
Primary completion
Feb 12, 2026
Completion
Apr 27, 2026
Last update
Nov 9, 2026

Study contacts

Gaku Nakazawa, MD, PhD
principal investigator · Kindai University Faculty of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester

Start the discussion